Welcome to Vicept

vicept - n. from Latin vita- life; and receptus (recipere) - to take back

A privately held specialty biopharmaceutical start-up focused on creating products for use in the largest and fastest growing sectors of the dermatology market.

Company founded with the mission to develop the first effective topically-applied treatment for the erythema (skin redness) associated with rosacea.

Innovator in the development of ()-adrenergic receptor technology pursuing indications which include the treatment and prevention of Rosacea, Actinic (Solar) Purpura and peri-procedural bruising of the skin.

Recent News

July 19, 2011
Allergan, Inc. to acquire privately held dermatologic company, Vicept Therapeutics.

View Press Release

April 19, 2011
Vicept Therapeutics Announces Positive Results from a Second Phase II Study of V-101 for the
Treatment of Type I Rosacea.

View Press Release

February 14, 2011
Vicept Therapeutics Secures $2.5M in Venture Debt Financing.

View Press Release